Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Amgen Inc AMGN

Healthcare Biotechnology
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL... see more

Opinion & Analysis (NDAQ:AMGN)

    Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

    Gail Dutton October 15, 2015

    Biotech Bears Spark Good Vibes For These ETFs

    Benzinga.com  October 6, 2015

    BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

    Gail Dutton October 1, 2015

    The Other Bearish Biotech ETF Is Looking Groovy, Too

    Benzinga.com  August 21, 2015

    Even With Recent Declines, Investors Still Love Biotech ETFs

    Benzinga.com  July 30, 2015

    A Big Day For Biotech And It's Not Going So Well

    Benzinga.com  July 27, 2015

    Play the gap to profit from Australia's undervalued biotech gems: John Hester of Bell Potter Securities

    George S. Mack July 22, 2015

    Zacks' Jason Napodano is not focused on a biotech bubble

    George S. Mack July 9, 2015

    ProShares Releases 2 New Leveraged Biotech ETFs

    Benzinga.com  June 23, 2015

    Biotech ETFs Hit New 2015 Highs

    Benzinga.com  June 18, 2015

    Capitalize on comeback stories in micro-cap biotech: Joe Pantginis of ROTH Capital Partners

    George S. Mack June 17, 2015

    The Best And Worst ETFs Of The Week Amid Biotech Rebound

    Benzinga.com  May 9, 2015

    3 Biotech ETFs Rally On Merger News

    Benzinga.com  December 8, 2014

    A Look At 3 Overbought ETFs

    Benzinga.com  December 2, 2014

    Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary

    Benzinga.com  October 30, 2014

    Drug ETFs Attractive Buys On Pullback

    Benzinga.com  October 22, 2014

    Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga.com  August 27, 2014

    Healthcare ETFs Leading the Pack This Q2 Earnings - ETF News And Commentary

    Benzinga.com  August 7, 2014

    Biotech ETFs Come Back Down To Earth

    Benzinga.com  March 27, 2014

    Seven portfolio cash cows that point the way to profit

    Larry D. Spears May 5, 2010